Intellipharmaceutics International Inc. (IPCI)

[numbersarefun]

doogdilinger, final 2 doses offset by exclusivity ending. Exclusivity on 25mg and 35mg FocalinXR ending soon, since they were launched in early January 2017. Par's market share for the two doses with exclusivity should decline. I would expect that the price for the two doses should also fall in line closer to the price of the other doses with more competition entering the market. So I would say that the two events, exclusivity ending and launching final 2 doses, offset each other.

It looks like 25mg and 35mg are currently about $100 more expensive than the other doses according to prices at goodrx.com. I would guess patients feel overcharged for 25mg and 35mg.

target(CVS):
25mg $267
35mg $280

5mg $171
10mg $206
15mg $160
20mg $194
30mg $163

doogdilinger wrote: "Me too wimusky PAR could be launching final 2 strengths anytime now through next Friday and if/when they do we should definitely be getting a PR to that effect!"